Skip to main content
. 2019 Feb 8;13(4):725–737. doi: 10.1002/1878-0261.12411

Figure 4.

Figure 4

The PrPC/FOXO3a/KLF5 axis expression correlates with colorectal cancer patient progression and is a marker for outcome. (A) Representative images of negative and positive immunohistochemical staining of PrPC, FOXO3a, and KLF5 from liver metastases, scale bar 100 μm. (B) Changes in positive staining percentages for PrPC, FOXO3a, and KLF5 in 11 matched primary colorectal cancer and liver metastases. (C) Representative images of negative and positive KLF5 staining of BRAF‐mutant microsatellite stable (MSS) and BRAF‐mutant microsatellite unstable (MSI) cancers, scale bar 100 μm. (D) Comparison of PrPC and KLF5 in BRAF‐wild‐type and BRAF‐mutant cancers, stratified by microsatellite instability (significance measured by two‐tailed Student's t‐test **P < 0.005). (E) Gene expression correlation with overall survival in 46 patients with aggressive Grade 3 colon cancer (significance determined by logrank test).